pyridoxamine has been researched along with Insulin Sensitivity in 9 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Obesity is associated with an increased risk for the development of type 2 diabetes and vascular complications." | 5.43 | Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet-Induced Obese Mice. ( Brouwers, O; Cleutjens, JP; Gaens, KH; Janssen, BJ; Maessen, DE; Miyata, T; Schalkwijk, CG; Stehouwer, CD; Wouters, K, 2016) |
| "It appears that pyridoxamine ameliorated lipid peroxidation and insulin resistance in KK-A(y)/Ta mice." | 3.75 | Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice. ( Gohda, T; Hagiwara, S; Horikoshi, S; Ishikawa, Y; Murakoshi, M; Ohara, I; Tanimoto, M; Tomino, Y; Toyoda, H, 2009) |
| "The advanced glycation end product inhibitor pyridoxamine (PYR) and the antioxidant alpha-lipoic acid (LA) interact to ameliorate insulin resistance in obese Zucker rats following short-term (6-week) treatment." | 3.75 | Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats. ( Diehl, CJ; Hasselwander, O; Henriksen, EJ; Lindborg, KA; Matuschek, M; Muellenbach, EM; Teachey, MK, 2009) |
| "Obesity is associated with an increased risk for the development of type 2 diabetes and vascular complications." | 1.43 | Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet-Induced Obese Mice. ( Brouwers, O; Cleutjens, JP; Gaens, KH; Janssen, BJ; Maessen, DE; Miyata, T; Schalkwijk, CG; Stehouwer, CD; Wouters, K, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, J | 2 |
| Tao, H | 2 |
| Yancey, PG | 2 |
| Leuthner, Z | 2 |
| May-Zhang, LS | 2 |
| Jung, JY | 2 |
| Zhang, Y | 2 |
| Ding, L | 2 |
| Amarnath, V | 2 |
| Liu, D | 2 |
| Collins, S | 2 |
| Davies, SS | 2 |
| Linton, MF | 2 |
| Van den Eynde, MDG | 1 |
| Houben, AJHM | 1 |
| Scheijen, JLJM | 1 |
| Linkens, AMA | 1 |
| Niessen, PM | 1 |
| Simons, N | 1 |
| Hanssen, NMJ | 1 |
| Kusters, YHAM | 1 |
| Eussen, SJMP | 1 |
| Miyata, T | 2 |
| Stehouwer, CDA | 1 |
| Schalkwijk, CG | 2 |
| Chiazza, F | 1 |
| Cento, AS | 1 |
| Collotta, D | 1 |
| Nigro, D | 1 |
| Rosa, G | 1 |
| Baratta, F | 1 |
| Bitonto, V | 1 |
| Cutrin, JC | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Collino, M | 1 |
| Maessen, DE | 1 |
| Brouwers, O | 1 |
| Gaens, KH | 1 |
| Wouters, K | 1 |
| Cleutjens, JP | 1 |
| Janssen, BJ | 1 |
| Stehouwer, CD | 1 |
| Ren, X | 1 |
| Sun, H | 1 |
| Zhang, C | 1 |
| Li, C | 1 |
| Wang, J | 1 |
| Shen, J | 1 |
| Yu, D | 1 |
| Kong, L | 1 |
| Muellenbach, EA | 1 |
| Diehl, CJ | 2 |
| Teachey, MK | 2 |
| Lindborg, KA | 2 |
| Archuleta, TL | 1 |
| Harrell, NB | 1 |
| Andersen, G | 1 |
| Somoza, V | 1 |
| Hasselwander, O | 2 |
| Matuschek, M | 2 |
| Henriksen, EJ | 2 |
| Murakoshi, M | 1 |
| Tanimoto, M | 1 |
| Gohda, T | 1 |
| Hagiwara, S | 1 |
| Ohara, I | 1 |
| Toyoda, H | 1 |
| Ishikawa, Y | 1 |
| Horikoshi, S | 1 |
| Tomino, Y | 1 |
| Muellenbach, EM | 1 |
| Unoki-Kubota, H | 1 |
| Yamagishi, S | 1 |
| Takeuchi, M | 1 |
| Bujo, H | 1 |
| Saito, Y | 1 |
1 trial available for pyridoxamine and Insulin Sensitivity
| Article | Year |
|---|---|
Pyridoxamine reduces methylglyoxal and markers of glycation and endothelial dysfunction, but does not improve insulin sensitivity or vascular function in abdominally obese individuals: A randomized double-blind placebo-controlled trial.
Topics: Female; Glycation End Products, Advanced; Humans; Insulin Resistance; Magnesium Oxide; Maillard Reac | 2023 |
8 other studies available for pyridoxamine and Insulin Sensitivity
| Article | Year |
|---|---|
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Scavenging dicarbonyls with 5'-O-pentyl-pyridoxamine increases HDL net cholesterol efflux capacity and attenuates atherosclerosis and insulin resistance.
Topics: Animals; Atherosclerosis; Cholesterol; Cholesterol, HDL; Female; Glucose; Inflammation; Insulin Resi | 2023 |
Protective Effects of Pyridoxamine Supplementation in the Early Stages of Diet-Induced Kidney Dysfunction.
Topics: Albumins; Animals; Body Weight; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 2017 |
Delayed Intervention With Pyridoxamine Improves Metabolic Function and Prevents Adipose Tissue Inflammation and Insulin Resistance in High-Fat Diet-Induced Obese Mice.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Arrhythmias, Cardiac; Cells, Cultured; Diet, High-Fat; Drug A | 2016 |
Protective function of pyridoxamine on retinal photoreceptor cells via activation of the p‑Erk1/2/Nrf2/Trx/ASK1 signalling pathway in diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease M | 2016 |
Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat.
Topics: Animals; Antioxidants; Blood Glucose; Drug Interactions; Fatty Acids, Nonesterified; Female; Glucose | 2008 |
Pleiotropic effect of pyridoxamine on diabetic complications via CD36 expression in KK-Ay/Ta mice.
Topics: Adipose Tissue; Animals; CD36 Antigens; Diabetes Complications; Diabetes Mellitus, Experimental; Dia | 2009 |
Metabolic interactions of AGE inhibitor pyridoxamine and antioxidant alpha-lipoic acid following 22 weeks of treatment in obese Zucker rats.
Topics: Animals; Antioxidants; Blood Glucose; Drug Synergism; Female; Glucose Tolerance Test; Glycation End | 2009 |
Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 2; Glycation End Products, Advanced; Insulin Resistance; Male; Mice | 2010 |